Huangpu manufactures new drug approved for market

Recently, Akeso Biopharma announced that its independently developed IL-12/IL-23 Ebdarokimab injection had been approved for market by the National Medical Products Administration.

Ebdarokimab injection. [Photo/WeChat account: gzhpfb]

This medication treats moderate to severe plaque psoriasis in adult patients who are unresponsive to systemic therapies like cyclosporine or PUVA, have contraindications, or cannot tolerate them.

Ebdarokimab is China's first domestically approved IL-12/IL-23 dual-target monoclonal antibody drug, demonstrating outstanding clinical efficacy and excellent safety. With a low dosing frequency of only four times a year, it offers a more efficient, safe, convenient, and cost-effective treatment option.

The market launch of this drug marks a new era of domestic production of IL-12/IL-23 monoclonal antibodies, providing a new choice for 6.7 million patients.

Furthermore, Akeso Biopharma's product strategy and competitiveness in non-oncology are increasingly strong.

Akeso Biopharma biopharmaceutical base. [Photo/WeChat account: gzhpfb]

Share - WeChat